EE.UU. debería apoyar al presidente electo Milei 10 de diciembre del 2023 La Nación …Milei es un aliado y EE.UU. debería apoyarlo. El presidente Joe Biden debería darle la bienvenida a Milei porque en estos momentos es difícil encontrar aliados en Latinoamérica y el...
News
Latest News
Rubio, Gallagher Statement on Biden Admin’s Watered-down Sanctions on Chinese Officials Conducting Genocide
The Biden Administration has been slow to implement sanctions under the Uyghur Human Rights Policy Act, which became law in 2020, and seeks to hold the perpetrators of the Uyghur genocide accountable. U.S. Senator Marco Rubio (R-FL) and U.S. Representative Mike...
Next Week: Rubio Staff Hosts Mobile Office Hours
In-person Mobile Office Hours Monday, December 11, 2023 Jackson County 9:30am – 11:00am CST UF/IFAS Jackson County Extension 2741 Penn Ave. Suite 3 Marianna, FL 32448 Click Here Pinellas County 1:30pm – 3:00pm EST Pinellas Park Chamber of Commerce 5851 Park...
Rubio, Colleagues Introduce Bill to Protect U.S. Schools From China’s Influence
Foreign adversaries, including China, have significantly increased covert tactics to infiltrate American colleges and K-12 schools. They do this to steal research, spread propaganda, and silence students and academics. U.S. Senator Marco Rubio (R-FL) and...
Rubio, Colleagues Issue Statement on Maduro Regime’s Harassment of Democratic Opposition
The criminal Maduro regime issued bogus warrants to arrest members of the Venezuelan opposition, including several campaign staffers working for opposition leader María Corina Machado, who won the opposition’s primary election earlier this year. Last night, Roberto...
Rubio Habla con Ninoska Pérez en La Poderosa
El senador estadounidense Marco Rubio (R-FL) habló con Ninoska Pérez en La Poderosa 670 AM, sobre los grupos en EE.UU. que apoyan la masacre que lidera Hamás contra Israel, sobre los reclamos para un cese de fuego, sobre el arresto de Manuel Rocha y más. Una...
Rubio Seeks Answers on Pharmacy Distribution of Abortion Drug
On January 3, 2023, the U.S. Food and Drug Administration (FDA) posted a new policy that allows pharmacies to distribute the chemical abortion pill mifepristone and remove the in-person distribution requirement. Data shows mifepristone is dangerous, which is why women using the drug to induce a chemical abortion were previously required to have medical supervision.
U.S. Senator Marco Rubio (R-FL) and Representative Andrew Clyde (R-GA) sent a letter to Government Accountability Office (GAO) Comptroller General Gene Dodaro urging the GAO to evaluate if the FDA’s change in guidance is considered a “rule” and subject to Congressional review under the Congressional Review Act.
- “We write to seek your review of whether the January 2023 REMS Modification for mifepristone, issued by the FDA, constitutes a ‘rule’ for purposes of the Congressional Review Act (CRA).”
- “The FDA’s update appears to prescribe detailed policy. For these reasons, we respectfully request a determination as to whether or not this ‘rule’ is applicable under the CRA. Please respond with your determination by February 14, 2023.”
Senators Cindy Hyde-Smith (R-MS), Mike Lee (R-UT), Thom Tillis (R-NC), Roger Marshall (R-KS), Mike Braun (R-IN), Rick Scott (R-FL), Roger Wicker (R-MS) and 27 members of the House also signed the letter.
Want more? The full text of the letter is below.
Dear Comptroller General Dodaro:
On January 3, 2023, the U.S. Food & Drug Administration (FDA) posted a new policy that increases access and consumption of mifepristone. We write to seek your review of whether the January 2023 REMS Modification for mifepristone, issued by the FDA, constitutes a “rule” for purposes of the Congressional Review Act (CRA).
With limited exceptions, the CRA defines a “rule” as follows:
‘[R]ule’ means the whole or part of an agency statement of general or particular applicability and future effect designed to implement, interpret, or prescribe law or policy or describing the organization, procedure, or practice requirements of an agency and includes the approval or prescription for the future of rates, wages, corporate or financial structures or reorganizations thereof, prices, facilities, appliances, services or allowances therefor or of valuations, costs, or accounting, or practices bearing on any of the foregoing.”
Based upon this broad definition, the Government Accountability Office has rightly pointed out that “agency pronouncements may be rules within the definition of 5 U.S.C. § 551 and the CRA, even if they are not subject to notice and comment rulemaking requirements under section 553.”
The FDA’s update appears to prescribe detailed policy. For these reasons, we respectfully request a determination as to whether or not this “rule” is applicable under the CRA. Please respond with your determination by February 14, 2023.
Sincerely,